News
CAMBRIDGE, MA, USA I June 18, 2025 I Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback